<DOC>
	<DOC>NCT02753582</DOC>
	<brief_summary>The primary objective is to determine the effect of SOD enzyme on frailty and health related quality of life among Indonesian pre-frail elderly. The secondary objective is to determine the effect of SOD enzyme on anti-oxidant status, morbidity, and hospitalization among Indonesian pre-frail elderly. The study hypothesis: 1. SOD enzyme can improve frailty status and health related quality of life among Indonesian pre-frail elderly. 2. SOD enzyme can increase anti-oxidant serum status among Indonesian pre-frail elderly. 3. SOD enzyme can decrease morbidity among Indonesian pre-frail elderly. 4. SOD enzyme can decrease hospitalization events among Indonesian pre-frail elderly.</brief_summary>
	<brief_title>The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial</brief_title>
	<detailed_description>1. Study design: randomized double blind placebo controlled trial. 2. Location and time of study: Geriatric Outpatient Clinic and Internal Medicine Outpatient Clinic in Cipto Mangunkusumo National Hospital Jakarta. Study will be conducted on April 2016 to April 2017. 3. Study subject: elderly outpatient (aged 60 years old or more) with pre-frail status, who visit the clinic for medical consultation. 4. Data sampling: consecutive method. 5. Sample size: 150 subjects (75 control group, 75 intervention group). 6. Data collection: demographic data, frailty status, health related quality of life, anthropometric data, anti-oxidant serum status, hospitalization during intervention, morbidity, nutritional status, food intake, hand grip strength. 7. Intervention: SOD+Gliadin in capsule with a dose of 250 mg twice a day for 24 weeks will be given to intervention group, while placebo group will be given placebo capsule (amylum).</detailed_description>
	<mesh_term>Superoxide Dismutase</mesh_term>
	<criteria>Elderly aged 60 years or more with prefrail condition Patients with SOD enzyme deficiency Willing to participate Patients with cognitive function impairment (AMT score &lt; 8) Patients with depression (Geriatric depression scale score &gt;= 10) Patients with history of cirrhotic hepatic disease or severe hepatic disease Patients with kidney function impairment Patients with gluten allergy and derivative products Patients consume other antioxidant and omega3 supplement</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Elderly, pre-frail, SOD</keyword>
</DOC>